1. Home
  2. OTEX vs LQDA Comparison

OTEX vs LQDA Comparison

Compare OTEX & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Open Text Corporation

OTEX

Open Text Corporation

HOLD

Current Price

$28.06

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

LQDA

Liquidia Corporation

SELL

Current Price

$40.20

Market Cap

5.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
OTEX
LQDA
Founded
1991
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
5.5B
IPO Year
1998
2020

Fundamental Metrics

Financial Performance
Metric
OTEX
LQDA
Price
$28.06
$40.20
Analyst Decision
Hold
Buy
Analyst Count
12
8
Target Price
$27.95
★ $54.38
AVG Volume (30 Days)
1.2M
★ 4.8M
Earning Date
11-05-2026
11-06-2026
Dividend Yield
★ 4.01%
N/A
EPS Growth
★ 56.36
51.81
EPS
★ 2.58
1.26
Revenue
★ $2,815,241,000.00
$158,320,000.00
Revenue This Year
N/A
$357.27
Revenue Next Year
$1.67
$1.34
P/E Ratio
★ $10.81
$31.31
Revenue Growth
22.88
★ 1031.18
52 Week Low
$19.78
$22.05
52 Week High
$39.81
$93.61

Technical Indicators

Market Signals
Indicator
OTEX
LQDA
Relative Strength Index (RSI) 80.34 44.79
Support Level $21.79 $35.00
Resistance Level N/A $40.60
Average True Range (ATR) 0.77 2.74
MACD 0.49 2.19
Stochastic Oscillator 99.66 99.91

Price Performance

Historical Comparison
OTEX
LQDA

About OTEX Open Text Corporation

Open Text Corp provides data management for enterprise AI, offering a secure data foundation and trusted context for credible AI outcomes across private, public, and sovereign cloud, managed cloud services, API, and on-premises environments. The Company also provides cybersecurity solutions to protect sensitive data, applications and systems across complex hybrid environments, including identity and access management, threat detection and response, data protection and application security. It serves private, public, and regulated sectors, including retail, financial services, government, manufacturing, healthcare, energy, and logistics, with clients. Geographically, it derives maximum revenue from the Americas.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: